Mesothelioma Drug Awarded Status by FDA
A recent article on reuters.com stated that the U.S. Food and Drug Administration (FDA) gave orphan drug status to an experimental drug produced by AstraZeneca used to treat mesothelioma. Tremelimumab is an immuno-oncology treatment which uses the body’s own immune system to fight the cancer. Orphan drug status is given by the FDA to encourage the development of drugs to combat rare diseases which are defined as those affecting less than 200,000 people. These drugs receive seven years of marketing exclusivity.